PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.15%
R&D reduction while TRAW shows 14.94% growth. Joel Greenblatt would examine competitive risk.
-30.87%
G&A reduction while TRAW shows 4.33% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.35%
Operating expenses reduction while TRAW shows 11.57% growth. Joel Greenblatt would examine advantage.
-30.35%
Total costs reduction while TRAW shows 11.57% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-2.47%
D&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
30.79%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.35%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-41.49%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
30.26%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
30.26%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.58%
EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
33.88%
Diluted EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
0.94%
Share count increase while TRAW reduces shares. John Neff would investigate differences.
5.92%
Diluted share increase while TRAW reduces shares. John Neff would investigate differences.